April is Testicular Cancer, Esophageal Cancer and Head & Neck Cancer Awareness Month
|
|
-
Disparities in Clinical Trials webinar this Thursday MOASC News/MOASC Programs
-
Medi-Cal Rx monthly bulletin has been published California News
-
New changes in HCPCS drug codes Medicare News/ CMS News
-
ICER report on novel agents to prevent chemotherapy-induced neutropenia National News
|
|
MOASC Programs - Save the Dates - All Times are Pacific
|
|
Please go to this link for details on the following outstanding programs MOASC brings to you.
-
This Thursday, April 7, 5:30pm! Disparities in Clinical Trials, a clinical webinar.
-
April 21, 5:30pm, Personalized Approaches to HER2+ Breast Cancer Treatment.
-
April 28, 7:00pm, GvHD: Acute and Chronic, the 2 types of cases will be discussed.
-
April 30, 8:00am, 1st Annual Santa Monica Melanoma Symposium.
-
May 3, 7:00pm, Myelofibrosis: High-Risk Primary Myelofibrosis roundtable.
|
|
Career News
Sign up now to receive the MOASC Job Flash™! Please activate your new job alert.
|
|
MOASC Clinical Trial Database is on the MOASC website at www.moasc.org
|
|
Medi-Cal Rx monthly bulletin for April 2022 has been published. Highlights are: Changes to the Contract Drugs List (CDL); Changes to the Contract Drugs List (CDL) – Over-the-Counter Drugs; Changes to the Contract Drugs List (CDL) – Authorized Drug Manufacturer Labeler Codes; Updates to the Medi-Cal Rx Provider Manual; Claim Edit Prescriber Enrollment; Claim Edit Prescriber Enrollment; Medi-Cal Rx Drug Lookup Tool and Contract Drugs List; Medi-Cal Rx Provider Portal Troubleshooting and Support.
|
|
ICER published research protocol for assessing price increases of prescription drugs in California. Final assessment to be published on October 13, 2022. Drugs to be evaluated are those identified through California’s SB-17 drug price transparency report.
|
|
California is working to establish a statewide health information exchange that would cover the state's 40 million residents. The state's Health and Human Services Agency is expected to complete a framework for the exchange by July.
|
|
Billing and Coding: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer (A57329) - R3 - Effective February 24, 2022.
|
|
Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors (A57901) - R1 - Effective January 01, 2022.
|
|
Billing and Coding: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease (A57421) - R6 - Effective March 17, 2022.
|
|
Billing and Coding: MolDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer (A55624) - R8 - Effective March 16, 2022
|
|
Please go to this link for details on the following Noridian programs
-
April 6, Physician Assistants and Practice Ownership Webinar
-
April 14, Quarterly Medicare Updates - A/B - After Hour
-
April 20, Ask the Contractor Teleconference (ACT)
|
|
April 1 brings new changes in HCPCS drug codes, Medicare drug allowables, HOPPS, “buy & bill,” and Sequestration returns to minus 1%.
|
|
ICER published evidence report on novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects.
|
|
Anthem Blue Cross is the latest payor to halt the reimbursement of consultation services. Effective January 1, 2022, Anthem is no longer reimbursing for inpatient and outpatient consultation CPT codes 99241-99245 and 99251-99255 for its for commercial insurance products. Instead, providers will need to bill utilizing the appropriate evaluation and management (E/M) procedure code that describes the office visit, hospital care, nursing facility care, home service or domiciliary/rest home care.
|
|
Medical coding experts say physicians should make sure their most common services are properly coded, that time spent is properly documented and that nonpatient-facing activities are tracked and coded.
|
|
April 2022 policy and protocol updates from UnitedHealthcare are now available
|
|
Affiliate Association News |
|
Applications for ANCO’s Travel Awards to Fellows and Young Clinicians to support attendance at the ASCO Annual Meeting, ASH Annual Meeting, or other national oncology meeting in 2022 are now being accepted. The deadline for submission is April 14th. Awards will be announced by April 30.
|
|
Exact Sciences announced that the ONCOTYPE MAPTM PAN-CANCER TISSUE TEST, is now available for Medi-Cal and Medicare patients. ONCOTYPE MAPTM Pan-Cancer Tissue Test is a rapid CGP test that helps guide therapy selection for patients with solid tumors. This test Utilizing minimal tumor tissue, the test identifies actionable genomic alterations within 3-5 business days*, allowing physicians to discuss treatment options with their patients in a timely manner.
|
|
Kite, a Gilead Company, announced that the FDA approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. It is not indicated for the treatment of patients with primary central nervous system lymphoma.
|
|
CTI BioPharma Corp. announced that the FDA approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1. The recommended dosage of VONJO is 200 mg orally twice daily. VONJO is the first approved therapy that specifically addresses the needs of patients with cytopenic myelofibrosis.
|
|
The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC accepts no liability for any statements or articles herein. CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.
|
|
|
|
|
|
|
